Xeris Pharmaceuticals | XERS - Sales Revenues


Xeris Pharmaceuticals reported $74.38M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Celltrion KRW 1.33T 300B Mar/2026
Cspc Pharmaceutical CNY 6.62B 358.95M Sep/2025
Deva Holding AS TRY 2.32B 418.58M Sep/2023
Dianthus Therapeutics USD 396K 203K Sep/2025
Divis Laboratories Ltd INR 26.04B 1.11B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Kangmei Pharma CNY 1.37B 101.16M Sep/2025
Knight Therapeutics CAD 92.26M 3.31M Sep/2024
Laboratorios Farma EUR 448.66M 67.82M Dec/2023
Medical Developments International AUD 9.53M 1.99M Jun/2025
Nektar Therapeutics USD 24.12M 635K Sep/2024
Neuren Pharmaceuticals AUD 14.14M 179.96M Jun/2025
Organigram Holdings CAD 80.06M 9.27M Sep/2025
Pacira USD 196.87M 17.35M Dec/2025
Perrigo USD 1.11B 70M Dec/2025
Pharma Mar EUR 35.7M 20.69M Sep/2025
Qiagen NV USD 457.38M 6.06M Dec/2025
Sartorius EUR 927.6M 84.4M Dec/2025
Sino Biopharmaceutical CNY 17.57B 4.58B Jun/2025
Supernus Pharmaceuticals USD 211.6M 19.5M Dec/2025
Tilray USD 217.51M 74.75M Dec/2025
Zhangzhou Pientzehuang Pharmaceutical CNY 2.88B 642.99M Sep/2025